Baluarte, Rowegen .
HRN: 24-30-56 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/27/2023
CO-AMOXICLAV 625MG (TAB)
12/27/2023
01/03/2024
PO
625mg
BID X 7 Days
PROM X 35 Hour; S/P NSVD
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes